Small IR agencies take the biotech lead but doubts gather about the longevity of the current biotech boom.
A once-troubled biotech industry appears finally to be growing up. Back in 2001-2002 the idea was unthinkable: biotech values had crashed as scientists-turned-entrepreneurs struggled to deliver on promises to shareholders, and the whole sector wore one huge warning label. Now, however, the biotech industry seems at risk of possibly becoming a clever – even mature – long-term buy.
Dr Navid Malik, a pharmaceuticals analyst from stockbrokers Collins Stewart, says the surge of interest
You need to register to access 3 free deep dive articles per month. To continue reading please register or login below..
- Unlimited deep dives
- Data-driven research around key topics
- Buy-side insights
- Benchmarking reports
From
$1495
Staff Writers
The staff writers on IR magazine are from our team of highly experienced journalists.
